A Study To Assess Relative Boavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 3/30/2013 |
| Start Date: | March 2013 |
| End Date: | April 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation Of Pf-05175157 And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation In Healthy Volunteers
The purpose of this study in healthy volunteers is to assess the relative boavailability of
PF-05175157 as powder-in-capsule and a tablet formulation and the effect of food on the
pharmacokinetics of the tablet formulation.
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive
- Women must be of non childbearing potential
- Body Mass Index (BMI) of 25 to 35 kg/m2; and a total body weight >50 kg (110 lbs)
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal
allergies at time of dosing) disease or clinical findings at Screening.
- Active ocular disease including infection, glaucoma, seasonal allergies, dry eye
symptoms, optic nerve disease or retinal disease.
- History of habitual smoking in the past 5 years or history or evidence of habitual
use of other (non smoked) tobacco or nicotine-containing products within 3 months of
Screening or positive cotinine test at Screening or Day 0
We found this trial at
1
site
Click here to add this to my saved trials
